Are you Dr. Karski?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 32 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
505 Parnassus Ave
M651
San Francisco, CA 94143Phone+1 415-476-3831
Summary
- Dr. Erin (Seiberlich) Karski, MD is a pediatric hematologist/oncologist in San Francisco, California. She is currently licensed to practice medicine in California and Minnesota. She is affiliated with UCSF Medical Center, Lucile Packard Children's Hospital Stanford, and Stanford Health Care.
Education & Training
- University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 2010 - 2013
- University of MinnesotaResidency, Pediatrics, 2007 - 2009
- University of MinnesotaInternship, Pediatrics, 2006 - 2007
- University of Minnesota Medical SchoolClass of 2006
Certifications & Licensure
- CA State Medical License 2010 - 2023
- MN State Medical License 2008 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
Publications & Presentations
PubMed
- 4 citationsPeripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma.Kevin Campbell, Erin E. Karski, Aleksandra Olow, David A. Edmondson, Ayano C. Kohlgruber
International Journal of Radiation Oncology, Biology, Physics. 2017-10-01 - 12 citationsPhase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.Kieuhoa T. Vo, Erin E. Karski, Nicole Nasholm, Shelly Allen, Fabienne Hollinger
Oncotarget. 2017-04-04 - 19 citationsTranscript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with 131I-mIBG, a Targeted RadionuclideDavid A. Edmondson, Erin E. Karski, Ayano C. Kohlgruber, Harsha Koneru, Katherine K. Matthay
Radiation Research. 2016-08-24